Files and links (1)
Published, Version of Record (VoR)CC BY-NC-ND V4.0, Open
Journal article
Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
ACR open rheumatology, v 4(5), pp 447-456
May 2022
PMID: 35218320
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Axial disease is common and burdensome in patients with psoriatic arthritis (PsA). Human leukocyte antigen-B27 (HLA-B27) is a risk factor for axial PsA; treatment response by HLA-B27 status is inadequately characterized. This study evaluated responses to biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) overall and by HLA-B27 status in patients with PsA axial disease.
This observational study included participants in the CorEvitas (formerly Corrona) PsA/Spondyloarthritis Registry who initiated bDMARD or tsDMARD treatment at baseline, had a 6-month follow-up visit, fulfilled Classification Criteria for Psoriatic Arthritis, had a baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥4, and had known HLA-B27 status. Disease characteristics at baseline and 6 months were evaluated overall and by HLA-B27 status. Association between HLA-B27 status and treatment response was evaluated using an analysis of covariance model.
The analysis included 173 bDMARD or tsDMARD treatment initiations (54 [31.2%] among patients with HLA-B27+ status and 119 [68.8%] among patients with HLA-B27- status). BASDAI total and component scores decreased by ≤0.84 across groups after 6 months of bDMARD or tsDMARD therapy; these changes are not considered clinically meaningful. HLA-B27 status was not statistically significantly associated with changes in axial-related outcomes.
In patients with PsA axial disease, 6 months of bDMARD or tsDMARD therapy provided only mild improvements in axial-related outcomes, irrespective of HLA-B27 status. This continued high disease activity reflects a critical unmet need for focus on the axial domain of PsA and for additional safe and effective therapies for psoriatic axial disease.
Metrics
Details
- Title
- Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
- Creators
- Philip J Mease - Swedish Medical CenterSoumya D Chakravarty - Drexel UniversityRobert R McLean - CorEvitas, LLC, Waltham, Massachusetts.Taylor Blachley - CorEvitas, LLC, Waltham, Massachusetts.Toana Kawashima - CorEvitas, LLC, Waltham, Massachusetts.Iris Lin - Janssen Scientific Affairs, LLC, Horsham, Pennsylvania.Arthur Kavanaugh - University of California, San DiegoAlexis Ogdie - University of Pennsylvania School of Medicine, Philadelphia
- Publication Details
- ACR open rheumatology, v 4(5), pp 447-456
- Publisher
- Wiley
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Rheumatology
- Web of Science ID
- WOS:000761226300001
- Scopus ID
- 2-s2.0-85133335036
- Other Identifier
- 991019167651804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Rheumatology